STOCKHOLM – Japanese scientist Tasuku Honjo, who jointly won this year's Nobel Prize in physiology or medicine for his research on the immune system that contributed to cancer treatments, said Thursday that he believes most cancers will become treatable with immunotherapy by 2050. The 76-year-old professor and deputy director-general at the Kyoto University Institute for Advanced Study spoke at a news conference at the Karolinska Institute in Stockholm, joined by American scientist James Allison, who shared the prize. The discovery by Honjo and Allison -- on methods to inhibit negative immune regulation -- established a new principle for cancer treatment that stimulates the inherent ability of the human immune system to unleash attacks on tumor cells, according to the Nobel Assembly. Honjo said it may become possible to contain the growth of most cancer cells through such treatment, even if cancer cannot be completely eliminated, as he discussed the effectiveness of combination therapy using drugs in the development of which he and Allison were involved. The Kyoto native and his team discovered PD-1, a protein on immune cells that operates as a brake on the immune system.
Two immunologists, James Allison from the University of Texas Austin and Tasuku Honjo from Kyoto University, have won the 2018 Nobel Medicine Prize for research that has revolutionised the treatment of cancer. The pair were honoured'for their discovery of cancer therapy by inhibition of negative immune regulation,' the Nobel Assembly said. Immune checkpoint inhibitor therapy targets proteins made by some immune system cells, as well as some cancer cells. The proteins can stop the body's natural defences from killing cancer cells. The therapy is designed to remove this protein'brake' and allow the immune system to more quickly get to work fighting the cancer.
James Allison of the University of Texas and Tasuku Honjo of Kyoto University will share the 9-million-kronor ($1.01 million) prize for 2018. Researchers from the United States and Japan won the Nobel Prize in medicine on Monday for discoveries that help the body marshal its cellular troops to attack invading cancers. One cancer doctor said "an untold number of lives ... have been saved by the science that they pioneered." James Allison of the University of Texas and Tasuku Honjo of Kyoto University will share the 9-million-kronor ($1.01 million) prize for 2018. Their parallel work concerned proteins that act as brakes on the body's immune system.
STOCKHOLM – Japanese scientist Tasuku Honjo was awarded on Monday this year's Nobel Prize in physiology or medicine, for his discovery of a protein that contributed to the development of an immunotherapeutic drug against cancer. Honjo, a 76-year-old professor at Kyoto University, won the prize with U.S. national James Allison, the Nobel Assembly at the Karolinska Institute said. Honjo opened a pathway for a new cancer treatment by discovering the PD-1 protein, which is responsible for suppressing immune response. "I'm very honored and pleased to receive the Nobel Prize in physiology or medicine," Honjo told a news conference following the announcement. His method of treating cancer -- by controlling the protein's function to suppress immunity -- led to the development of Nivolumab, a drug marketed as Opdivo and used against lung cancer and melanoma.
While there are now scientific awards with larger monetary prizes, there is no prize so universally and immediately recognized as a sign of prestige. The 2018 season kicked off on Monday with the Nobel Prize in Physiology or Medicine, which this year honors two researchers for their work on cancer therapy. James P. Allison, 70, born in Alice, Texas, and now affiliated with the University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy in San Francisco, splits the prize with Tasuku Honjo, 76, a professor at Kyoto University in Japan. Their joint prize includes 9,000,000 Swedish Krona, which is a bit more than $1,000,000 USD. In the 1990s, Allison and Honjo did separate but parallel research on the use of the human immune system to fight cancer.